Oct 10, 2016 11:00 am UTC| Business
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ALPHARETTA, Ga., Oct. 10,...
Oct 10, 2016 11:00 am UTC| Business
BEVERLY, Mass., Oct. 10, 2016 -- Cellceutix Corporation, (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and...
Oct 10, 2016 11:00 am UTC| Business
-- Data, Including Developmental Milestones, as of September 15, 2016 as presented by Jerry Mendell, M.D. at the International Annual Congress of the World Muscle Society -- -- Webcast Today, October 10, 2016 at 8:30...
Oct 10, 2016 11:00 am UTC| Business
NUTH, The Netherlands and SAN DIEGO, Oct. 10, 2016 -- Fortimedix Surgical today announced the first-in-man use in the United States of FMX314, the world’s first single-port surgery solution that is compatible with a...
Great Basin Scientific Announces Transfer to the OTCQB Marketplace
Oct 10, 2016 11:00 am UTC| Business
SALT LAKE CITY, Oct. 10, 2016 -- Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today that its common stock will begin trading on the OTC Market Group’s OTCQB marketplace...
Oct 10, 2016 11:00 am UTC| Business
RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective Supinoxin™ was Safe and Well Tolerated in Patients with Advanced and Metastatic Solid Tumors...
Oct 10, 2016 11:00 am UTC| Business
BURLINGAME, Calif., Oct. 10, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today...